The March 2020 issue of Pharmafocus is available to read free online now!
pharmafile | February 27, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | England, Pharmafocus, UK, mumps, pharma, pharmacovigilance, type 2 diabetes
The latest monthly edition of Pharmafocus, the March issue, is available to read for free online now!
The coronavirus continues to spread and test the response strategies of nations around the world, and pharma and biotech companies are scrambling to develop interventions for the virus. Gilead is currently ahead in the race, with its therapy remdesivir thought to be potentially ready for approval in China as early as May this year. You can read the full story so far in our front page story.
On top of this global challenge, the UK also faces immediate trials of it own, as mumps cases hit a 10-year high in England and surging rates of type 2 diabetes in Wales and Scotland are heralded as an “urgent public health crisis”. You can catch up on the latest news in the UK here.
In this issue, we also have full-length features on the need for Pharmacovigilance functions to evolve in order to meet rapidly advancing technology and regulatory demands, and on the current state of pharmaceutical pricing and where the balance needs to be struck between access and innovation, looking at the UK, US, and German market access systems.
We also speak to 23-year-old US student Madelyn Lazra who recounts her experience living with type 1 diabetes and gives her thoughts on the difficulties she has experienced with the US pricing system, and Rami Levin, who discusses the lessons he has learned throughout his career on his journey to becoming CEO of the biotech firm Saniona.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
FDA approves new medicines to treat paediatric type 2 diabetes
The US Food and Drug Administration (FDA) has announced that it has approved Jardiance (empagliflozin) …
